TABLE 1.
Demographic and clinical characteristics of participants in the cohorts included in the Altoida database at baseline
| First study (Tarnasas et al. 2015) (n = 215) | Altoida ML study (NCT02843529) (n = 496) | |
|---|---|---|
| Follow‐up time, years | 4.5 (2.6) | 2.6 (1.6) |
| MCI subjects | 61 | 213 |
| Number of MCI subjects progressing to dementia | 37 (60%) | 100 (47%) |
| Number of MCI subjects with β‐amyloid biomarker progressing to AD dementia | 30 (49%) | 79 (37%) |
| MCI subjects progressing to other types of dementia | 7 (11%) | 21 (10%) |
| Average age, years (SD) | 72 (9) | 67 (8) |
| Female | 118 (55%) | 306 (62%) |
| Male | 97 (45%) | 190 (38%) |
| MMSE | 26 (2) | 27 (2) |
| Hippocampal volume, cm³ | 5.4 (1.6) | 6.2 (1.2) |
| CSF biomarkers, pg/ML | ||
| Amyloid beta (Aβ1‐42) | 925 (297) | 790 (378) |
| Total tau (t‐tau and p‐tau‐181/tau ratio) | 286 (191) | 270 (140) |
| Phosphorylated tau (p‐tau‐181/p‐tau231) | 27 (15) | 33 (18) |
Data are n (%) or mean (SD).
Abbreviations: AD, Alzheimer's diseaseCSF, cerebrospinal fluid; MCI, mild cognitive impairment; MMSE, Mini‐Mental State Examination; SD, standard deviation.